Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of NASDAQ ADXS opened at $0.11 on Friday. The firm has a market capitalization of $4.48 million, a P/E ratio of -0.01 and a beta of 1.81. Ayala Pharmaceuticals has a one year low of $0.00 and a one year high of $1.49. The company’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.16.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.